- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 5.1 Opinion of Goodwin Procter LLP
- 10.3 Form of Subscription Agreement
- 10.6 Distribution Agreement, Dated June 25, 2018, by and Between Fresenius Medical Care Holdings, Inc. and Humacyte, Inc
- 10.6 First Amendment to Distribution Agreement, Dated October 2, 2019, by and Between Fresenius Medical Care Holdings, Inc. and Humacyte, Inc
- 10.6 Second Amendment to Distribution Agreement, Effective As of February 16, 2021, by and Between Fresenius Medical Care Holdings, Inc. and Humacyte, Inc
- 10.7 Exclusive License Agreement, Dated February 25, 2014, by and Between Yale University and Humacyte, Inc
- 10.8 Exclusive License Agreement, Dated August 13, 2019, by and Between Yale University and Humacyte, Inc
- 10.9 Exclusive License Agreement, Dated August 25, 2019, by and Between Yale University and Humacyte, Inc
- 10.10 Exclusive Patent License Agreement, Dated March 14, 2006, Between Duke University and Humacyte, Inc
- 10.10 First Amendment to Exclusive Patent License Agreement, Dated February 25, 2011, Between Duke University and Humacyte, Inc.
- 10.10 Second Amendment to Exclusive Patent License Agreement, Dated April 24, 2014, Between Duke University and Humacyte, Inc
- 10.10 Third Amendment to Exclusive Patent License Agreement, Dated June 26, 2015, Between Duke University and Humacyte, Inc
- 10 Fourth Amendment to Exclusive Patent License Agreement, Dated January 2, 2018, Between Duke University and Humacyte, Inc
- 10.10 Fifth Amendment to Exclusive Patent License Agreement, Dated December 31, 2019, Between Duke University and Humacyte, Inc
- 10.11 Supply Agreement, Dated January 9, 2014, Between Seracare Life Sciences, Inc. and Humacyte, Inc
- 10.11 First Amendment to Supply Agreement, Dated October 12, 2018, Between Seracare Life Sciences, Inc. and Humacyte, Inc
- 10.12 Supply Agreement, Dated August 31, 2015, Between Confluent Medical Technologies (Formerly Known As Biomedical Structures LLC) and Humacyte, Inc
- 10.13 Executive Employment Agreement, Dated February 3, 2021, Between Laura Niklason, M.D., PH.D. and Humacyte, Inc
- 10.14 Executive Employment Agreement, Dated June 19, 2018, Between Jeffrey Lawson, M.D. and Humacyte, Inc
- 10.14 Amendment to Executive Employment Agreement, Dated February 3, 2021, Between Jeffrey Lawson, M.D. and Humacyte, Inc
- 10.15 Executive Employment Agreement, Dated October 8, 2018, Between Douglas Blankenship and Humacyte, Inc
- 10.16 Executive Employment Agreement, Dated September 13, 2019, Between Heather Prichard, PH.D. and Humacyte, Inc
- 10.18 Humacyte, Inc. 2005 Stock Option Plan
- 10.18 First Amendment of Humacyte, Inc. 2005 Stock Option Plan, Dated March 31, 2008
- 10.18 Second Amendment of Humacyte, Inc. 2005 Stock Option Plan, Dated October 28, 2011
- 10.18 Third Amendment of Humacyte, Inc. 2005 Stock Option Plan, Dated November 22, 2013
- 10.18 Form of Incentive Stock Option Agreement Under Humacyte, Inc. 2005 Stock Option Plan
- 10.18 Form of Nonstatutory Stock Option Agreement Under Humacyte, Inc. 2005 Stock Option Plan
- 10.19 Humacyte, Inc. 2015 Omnibus Incentive Plan
- 10.19 First Amendment to Humacyte, Inc. 2015 Omnibus Incentive Plan, Dated February 23, 2018
- 10.19 Second Amendment to Humacyte, Inc. 2015 Omnibus Incentive Plan, Dated June 6, 2018
- 10.19 Form of Incentive Stock Option Agreement Under Humacyte, Inc. 2015 Omnibus Incentive Plan
- 10.19 Form of Nonstatutory Stock Option Agreement Under Humacyte, Inc. 2015 Omnibus Incentive Plan
- 10.20 Annual Bonus Plan
- 10.22 Lease Agreement, Dated December 31, 2015, Between Are-nc Region No. 5, LLC and Humacyte, Inc
- 10.22 First Amendment to Lease, Dated September 30, 2016, Between Are-nc Region No. 5, LLC and Humacyte, Inc
- 10.22 Second Amendment to Lease, Dated February 8, 2017, Between Are-nc Region No. 5, LLC and Humacyte, Inc
- 10.22 Third Amendment to Lease, Dated April 21, 2017, Between Are-nc Region No. 5, LLC and Humacyte, Inc
- 10.22 Fourth Amendment to Lease, Dated October 31, 2017, Between Are-nc Region No. 5, LLC and Humacyte, Inc
- 21.1 Subsidiaries of Alpha Healthcare Acquisition Corp
- 23.2 Consent of Marcum LLP
- 23.3 Consent of Pricewaterhousecoopers LLP
- 99.3 Consent of Laura E. Niklason, M.D., PH.D
- 99.4 Consent of Brady W. Dougan
- 99.5 Consent of Emery N. Brown, M.D., PH.D
- 99.6 Consent of Kathleen Sebelius
- 99.7 Consent of Max Wallace, J.D
- 99.8 Consent of Susan Windham-bannister, PH.D
- 5 Aug 21 EFFECT Notice of effectiveness
- 4 Aug 21 424B3 Prospectus supplement
- 2 Aug 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Jul 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Jul 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 14 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
23 Mar 21 S-4 Registration of securities issued in business combination transactions
- 23 Jul 21 Registration of securities issued in business combination transactions (amended)
- 1 Jul 21 Registration of securities issued in business combination transactions (amended)
- 14 Jun 21 Registration of securities issued in business combination transactions (amended)
- 23 Mar 21 Registration of securities issued in business combination transactions
Exhibit 10.6.1
FIRST AMENDMENT TO DISTRIBUTION AGREEMENT
This First Amendment to Distribution Agreement, made as of this 2nd day of October, 2019 (the “Effective Date”), is by and between Fresenius Medical Care Holdings, Inc. (“Fresenius”) and Humacyte, Inc. (“Humacyte”) (collectively, the “Parties”).
WHEREAS, the Parties are parties to that Distribution Agreement dated June 25, 2018 (the “Agreement”); and
WHEREAS, the Parties wish to amend the Agreement pursuant to the terms and conditions described herein.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree to amend the Agreement as follows:
1. | Section 2.2.1 of the Agreement is hereby deleted in its entirety and replaced by the following as of the Effective Date: |
“2.2.1 Composition. Each Party will appoint [***] to the JSC, with each representative [***]. As of the Effective Date, as defined in the First Amendment to Distribution Agreement, such representatives are as follows:
Humacyte Appointees: [***] | Fresenius Appointees: [***] |
The Humacyte [***]. The JSC may change its size from time to time by consent of the Parties, provided that the JSC will consist at all times of an equal number of representatives of each Party. [***] The JSC may invite non-members to participate in the discussions and meetings of the JSC, but such participants will have no voting authority at the JSC and must be bound under written obligations of confidentiality no less protective of the Parties’ Confidential Information than those set forth in this Agreement. The JSC will be co-chaired, with one (1) chairperson designated by each Party, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JSC will alternate between the chairpersons from meeting-to-meeting, with Fresenius’ chairperson running the first meeting. The chairperson for a particular meeting will prepare and circulate agendas in advance thereof and will ensure the preparation and approval of minutes for such meeting. The chairpersons have no additional powers or rights beyond those held by the other JSC representatives.”
2. | Except as otherwise amended by the terms herein, all terms and conditions of the Agreement shall remain in full force and effect and are hereby affirmed and ratified. |
IN WITNESS WHEREOF, the Parties have executed this First Amendment to Distribution Agreement on the dates shown below.
FRESENIUS: | HUMACYTE: | |||
Fresenius Medical Care Holdings, Inc. | Humacyte, Inc. | |||
By: | /s/ William Valle | By: | /s/ Jeffrey Lawson | |
Name: | William Valle | Name: | Jeffrey Lawson | |
Its: | President | Its: | CEO | |
Date: | 10/7/19 | Date: | October 2, 2019 |